UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-42139 Actuate Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware (State or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ___________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact name of registrant as specified in its charter) ___________________________ Delaware 93-4440048 (I.R.S. Employer Identification No.) For the quarterly period ended March 31, 2025 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition pe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _________ to _________ Commission file number: 001-41227 CISO GLOBAL, INC. (Exact name of registrant as specified in its charter) (State or other Jurisdiction of Incorpo ...

Financial Position - Immunic, Inc. reported an accumulated deficit of approximately $536.9 million as of March 31, 2025, up from $511.4 million as of December 31, 2024[152]. - As of March 31, 2025, Immunic had cash and cash equivalents of approximately $14.3 million, which is insufficient to fund operations for at least twelve months without raising additional capital[153]. - The company has not generated any revenue from product sales and does not expect to do so in the foreseeable future[162]. - Cash and cash equivalents were approximately $14.3 million as of March 31, 2025, indicating inadequate liquidity to fund operations for at least twelve months without raising additional capital[181]. - As of March 31, 2025, the Company had approximately $14.3 million in cash and cash equivalents[199]. - The Company filed a shelf registration statement in November 2023 allowing for the offering of up to $250 million in various securities, with a total shelf availability of approximately $412.3 million as of March 31, 2025[184]. - The Company incurred no cash from financing activities for the three months ended March 31, 2025, compared to $74.4 million in the same period of the previous year[205][206]. Clinical Trials and Product Development - The Phase 3 ENSURE program for vidofludimus calcium in relapsing multiple sclerosis (RMS) is ongoing, with completion expected in the second quarter of 2026[139]. - Positive interim data from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (PMS) showed substantial reductions in disability progression and thalamic brain volume[140]. - IMU-856 demonstrated positive effects in a Phase 1b clinical trial for celiac disease, including protection of gut architecture and improvement of symptoms[144]. - The company is preparing for a Phase 2 clinical trial of IMU-856 in patients with ongoing active celiac disease[144]. - Immunic is focused on executing ongoing clinical trials and exploring additional indications for its product candidates[150]. - Vidofludimus calcium reduced the relative risk of 24-week confirmed disability worsening by 30% in primary progressive multiple sclerosis patients compared to placebo[156]. - IMU-856 demonstrated a dose-dependent increase of endogenous GLP-1 levels in celiac disease patients, with significant increases of 80 mg (p=0.014) and 160 mg (p=0.003) compared to placebo[155]. Financial Performance - The company incurred a net loss of $25.5 million for the three months ended March 31, 2025, a decrease of 14% compared to a net loss of $29.6 million for the same period in 2024[173]. - Research and development expenses increased by $2.8 million (15%) to $21.5 million for the three months ended March 31, 2025, compared to $18.7 million for the same period in 2024[173][174]. - The total operating expenses for the three months ended March 31, 2025, were $26.8 million, an increase of 12% from $23.9 million in the same period in 2024[173]. - Interest income decreased by $1.0 million (85%) to $183,000 for the three months ended March 31, 2025, compared to $1.2 million for the same period in 2024[173][175]. - For the three months ended March 31, 2025, operating activities used $21.8 million in cash, primarily due to a net loss of $25.5 million[201]. Strategic Plans and Collaborations - Immunic plans to evaluate potential strategic collaborations to enhance the commercialization of its product candidates[151]. - The Company expects future expenses to increase as it continues research, development, and clinical trials for its product candidates[196]. - The Company has non-cancelable contractual obligations totaling approximately $2.6 million related to its development programs, expected to be paid in 2025 and 2026[210]. Currency and Inflation Risks - The company has significant exposure to foreign currency exchange rates, primarily the Euro and the Australian dollar, which could adversely affect financial results[214]. - A 10% change in currency exchange rates could materially impact the company's financial position, with a potential effect of approximately $1.3 million on net current liabilities as of March 31, 2025[216]. - For the three months ended March 31, 2025, a 10% change in foreign currency exchange rates would have impacted the company's net loss by approximately $2.0 million, primarily due to the Euro[216]. - The company has not entered into any foreign currency hedging transactions and does not have current plans to do so[214]. - The company has experienced a general increase in costs due to global inflation, but does not believe it has had a material impact on operations[217]. - The company’s German subsidiary is a significant portion of its business, and fluctuations in exchange rates could affect its consolidated financial position[215]. Accounting and Disclosure - The company has adopted ASU No. 2023-09 for income tax disclosures, effective January 1, 2025, which will improve the consistency and disaggregation of information[212]. - The company evaluates its accounting estimates and assumptions on an ongoing basis, which may differ from actual results under different conditions[211].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q For the transition period from to For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 BANNIX ACQUISITION CORP. (Exact Name of Registrant as Specified in its Charter) | Delaware | 001-40790 | 86-1626016 | | --- | --- | --- | | (State or other jurisdiction ...

Exhibit 99.1 RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights Q1 2025 RenovoCath Revenues of ~$200,000, Exceeding Expectations and Anticipated to Continue Growing Sequentially with New Customer Purchase Orders and Reorders Cash on Hand of $14.6 Million Anticipated to Fully Fund both RenovoCath Commercialization Scale-up and Continued Progress Towards the Completion of the Ongoing Phase III TIGeR-PaC Clinical Trial Looking ahead, RenovoRx sees expansion opportunities across other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39378 __________________________ ORIGIN MATERIALS, INC. (Exact name of registrant as specified in its charter) _________________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION (Exact name of registrant as specified in its charter) of incorporation or organization Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-41355 Sharps Technology, Inc. (I.R.S. Employer Identification No.) 105 Maxess Road, Melville, ...

Expion360 Reports First Quarter 2025 Financial Results Q1 2025 Revenue Growth of 111% Driven by New Products and Technologies 5th Consecutive Quarter of Robust Revenue Growth Began Shipping e360 Home Energy Storage Solutions REDMOND, OR – May 15, 2025 -- Expion360 Inc. (Nasdaq: XPON) ("Expion360" or the "Company"), an industry leader in lithium-ion battery power storage, today reported its financial and operational results for the first quarter ended March 31, 2025. Exhibit 99.1 "In January, we began produc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-42430 Tavia Acquisition Corp. (Exact Name of Registrant as Specified in Its Charter) Cayman Islands N/A (State or other jurisdiction of inc ...